The global pharmaceutical aseptic transfer market is projected to reach $2,551.5 million by 2031 from $855.2 million in 2021 at a CAGR of 9.61% during the forecast period 2022-2031. The growth in the global pharmaceutical aseptic transfer market is expected to be driven by the rapid expansion of the pharmaceutical industry, the significant rise of investment in the pharmaceutical industry, the implementation of stringent regulations for drug approval processes, and the growing demand for automated products for aseptic transfer processes.

Market Lifecycle Stage

The pharmaceutical aseptic transfer market is in the developed phase. The increasing demand for single-use aseptic transfer systems, increasing demand for liquid aseptic transfer systems, and the integration of Industry 4.0 within the pharmaceutical aseptic industry are some of the major opportunities in the global pharmaceutical aseptic transfer market. Furthermore, some of the key trends going on in the market are the shift from conventional cleanroom technology to barrier technology, the development of single-use transfer solutions, the rising demand for genderless aseptic connectors, and the increasing number of mergers and acquisitions (M&As) among market players.

Impact of COVID-19

The COVID-19 pandemic led to pharmaceutical companies investing heavily in R&D and ramping up production of potentially life-saving drugs for COVID-19. The unprecedented demand for these drugs and the urgency to cater to the demand within a short span of time led to higher demand for the maintenance of an aseptic environment in order to ensure regulatory compliance and faster time-to-market. However, the trade and travel restrictions amidst the COVID-19 pandemic placed a higher burden on the supply chain, with the procurement of components and systems becoming more challenging.

Overall, while the supply side was negatively impacted, especially during the peak of the COVID-19 pandemic, the significantly high demand for aseptic solutions offset the negative impact and led to positive growth of the market in 2020 and 2021.

Market Segmentation:

Segmentation 1: by System Type
• Liquid Transfer System
• Solid Transfer System

The global pharmaceutical aseptic transfer market (by system type) is expected to be dominated by the solid transfer system segment.

Segmentation 2: by Usability
• Single-Use
• Multiple-Use

The global pharmaceutical aseptic transfer market (by usability) is dominated by the multiple-use segment.

Segmentation 3: by Transfer Type
• Port
• Portbags
• Others

The global pharmaceutical aseptic transfer market (by transfer type) is dominated by the others segment.

Segmentation 4: by End User
• Pharmaceutical Companies
• Contract Development and Manufacturing Organizations (CDMOs)
• Others

The global pharmaceutical aseptic transfer market (by end user) is dominated by the pharmaceutical companies segment.

Segmentation 5: by Region
• North America – U.S., Canada
• Europe – Germany, France, U.K., Italy, Spain, Rest-of-Europe
• Asia-Pacific – Japan, China, India, Australia, South Korea, Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, Rest-of-Latin America
• Middle East and Africa – U.A.E., South Africa, Rest-of-Middle East and Africa

Recent Developments in Global Pharmaceutical Aseptic Transfer Market

• In June 2022, ChargePoint Technology acquired a single-use product and accessory manufacturer, Terracon.
• In January 2022, ChargePoint Technology accelerated expansion to enhance services in the U.S. market.
• In June 2022, Getinge AB launched its DPTE-EXO with sleeveless DPTE-BetaBag. This alpha port ensures automated aseptic transfer and assists in enhancing operational proficiency.
• In November 2021, Getinge AB extended its presence in Vietnam by forming its legitimate unit, Getinge Vietnam.
• In November 2021, Sartorius AG expanded its production capacities in France for storage and further innovation to meet the rising demands of the pharmaceutical industry.
• In September 2021, Sartorius AG expanded its manufacturing facilities in China in biological drug discovery, process development, testing, and validation to meet growing local customer demand.
• In March 2021, Arcline Investment Management acquired ChargePoint Technology to fuel an increased global presence.
• In January 2021, Getinge AB expanded the production capacity of its DPTE BetaBags in the U.S. by establishing the manufacturing of these BetaBags at its site in Merrimack, New Hampshire.
• In December 2020, Pall Corporation established a strategic partnership with Single Use Support GmbH to distribute the RoSS SHELL platform of the company globally.
• In June 2020, ABS Transfer SAS raised $3.2 million (€3 million), in the series A funding round led by Go Capital, along with Bpifrance and the regional government of Centre-Val de Loire.

Demand – Drivers and Limitations

Following are the drivers for the global pharmaceutical aseptic transfer market:

• Rapid Expansion of the Pharmaceutical Industry
• Significant Rise of Investment in the Pharmaceutical Industry
• Implementation of Stringent Regulations for Drug Approval Processes
• Growing Demand for Automated Products for Aseptic Transfer Processes

The market is expected to face some limitations too due to the following challenges:

• Complex Development Cycle of Aseptic Transfer Systems and Requirement of Large Capital Investment for Installation
• Lack of Skilled Personnel
• Growing Preference for Refurbished Equipment

How can this report add value to an organization?

Product/Innovation Strategy: The product segment helps the reader understand the different types of aseptic transfer products and accessories available for use in the pharmaceutical industry. Moreover, the study provides the reader with a detailed understanding of the different aseptic transfer products by system type (liquid transfer system and solid transfer system), usability (single-use and multiple-use), transfer type (ports, portbags, and others), and end user (pharmaceutical companies, contract development manufacturing organizations (CDMOs), and others).

Growth/Marketing Strategy: The global pharmaceutical aseptic transfer market has seen major development by key players operating in the market, such as business expansion, partnership, collaborations and business expansions, mergers and acquisitions, product launches, and funding activities. The favored strategy for the companies has been partnerships, alliances, and business expansions to strengthen their position in the global pharmaceutical aseptic transfer market. For instance, in June 2022, Tema Sinergie and AMERICAN FARMAGRUP S.A.S partnered to provide customized solutions for the pharmaceutical industry in South America.

Competitive Strategy: Key players in the global pharmaceutical aseptic transfer market analyzed and profiled in the study involve players that offer aseptic transfer products and services. Moreover, a detailed market share analysis of the players operating in the global pharmaceutical aseptic transfer market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent established names in this market are:

• ABC Transfer SAS
• ATS Automation Tooling Systems, Inc.
• Azbil Corporation
• Castus GmbH & Co. KG
• ChargePoint Technology
• Dover Corporation
• EnPro Industries, Inc.
• Entegris Inc.
• Ezi-Dock Systems Ltd.
• Getinge AB
• ILC Dover LP
• JCE Biotechnology
• Rommelag
• Sartorius AG
• Single Use Support GmbH

The post Pharmaceutical Aseptic Transfer Market – A Global and Regional Analysis: Focus on System Transfer, Transfer Type, Usability, End User, and Region – Analysis and Forecast, 2022-2031 first appeared on CRI Report.

Market Segmentation

• Product- Pre-filled syringes, multidose eyedroppers, squeeze dispensers, mist sprayers, add-on devices, contact lenses, and others (tubes, ocular inserts, etc.)
• Formulation- eye drops, liquid sprays, ointments, gels, and others (emulsions, suspensions, etc.)
• Sales channel- Direct sales and indirect sales
• End User- Hospitals, clinics, homecare settings, and others (standalone and specialty centers)

Regional Segmentation

• North America – U.S., and Canada
• Europe – Germany, U.K, France, Italy, Spain, Nordic Countries, and Rest-of-Europe
• Asia-Pacific – Japan, China, India, South Korea, Australia and New Zealand, Singapore, and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, Argentina, Colombia, and Rest-of-Latin-America
• Middle East and Africa – K.S.A., Israel, South Africa, and Rest-of-Middle East and Africa

Market Growth Drivers

• Rising Prevalence of Ocular Disorders
• Development of Novel Drug Dispensers
• Integration of Digital Solutions in Ophthalmic Drug Delivery Devices
• Regular Funding Cycles for Emerging Companies

Market Challenges

• High Upfront Cost of Advanced Ophthalmic Drug Delivery Devices
• Prolonged Regulatory Approval Process

Market Opportunities

• Entry of Regional Companies in Global Ophthalmic Drug Delivery Devices Market
• Partnerships Between Companies and Ophthalmic Clinics
• Inclusion of Nanotechnology in Ophthalmic Drugs Formulation

Key Companies Profiled

Aero Pump GmbH, AptarGroup, Inc., Bausch Health Companies Inc., Becton, Dickinson and Company, EyePoint Pharmaceuticals, Inc., Gaplast GmbH, Gerresheimer AG, Jotteq Inc., Nemera, Nipro Corporation, Ocular Therapeutix, Inc., Owen Mumford, Silgan Holdings Inc., Terumo Corporation, West Pharmaceutical Services, Inc., Kedalion Therapeutics, Inc., Re-Vana Therapeutics, Mati Therapeutics, Inc., Biocorp, Ocumedic, Inc.

How This Report Can Add Value

Who should buy this report?

• Technology/non-healthcare companies planning to enter the ophthalmic drug delivery devices market through a platform, mobile application, or smart device
• Ophthalmic drug delivery device manufacturers
• Companies manufacturing contact lenses

Key questions answered in the Global Ophthalmic Drug Delivery Devices Market Report

• What has been the impact of COVID-19 on the global ophthalmic drug delivery devices market?
• What are the key technological trends influencing the global ophthalmic drug delivery devices market, and what is their potential in short-, mid-, and long-term duration?
• What are the key regulations impacting the global ophthalmic drug delivery devices market?
• Who are the key players in the global ophthalmic drug delivery devices market?
• Which key strategy was most extensively used in the global ophthalmic drug delivery devices market?
• What are the key factors influencing the growth of the global ophthalmic drug delivery devices market? What are the major opportunity areas for the companies operating in the market?
• Which product sub-category is projected to witness accelerated growth in the global ophthalmic drug delivery devices market during the forecast period 2021-2030?
• Which formulation type is projected to hold the largest share in the global ophthalmic drug delivery devices market during the forecast period 2021-2030?
• What are the major sales channels in the global ophthalmic drug delivery devices market, and what is their growth potential during the forecast period 2021-2030?
• Who are the key end users, and what is their respective share in the global ophthalmic drug delivery devices market?
• What are the major key findings for the global ophthalmic drug delivery devices market across various regions?

Global Ophthalmic Drug Delivery Devices Market Overview

The scope of the global ophthalmic drug delivery devices market involves various drug delivery devices used in ophthalmic drug delivery. The considered devices include pre-filled syringes, multidose eyedroppers, drug-eluting contact lenses, technology-enabled add-on devices, mist sprayers, squeeze dispensers, and other devices such as tubes and ocular inserts.

The global ophthalmic drug delivery devices market comprises various key medical device companies and emerging companies. The major medical device companies operating in the market include Becton, Dickinson and Company, Nipro Corporation, Teruo Corporation, and West Pharmaceutical Services, Inc.

Furthermore, various ophthalmic drug delivery device manufacturers such as Aero Pump GmbH, AptarGroup, Inc., Bausch Health Companies Inc., EyePoint Pharmaceuticals, Inc., Gaplast GmbH, Gerresheimer AG, Jotteq Inc., Nemera, Ocular Therapeutix, Inc., Owen Mumford, and Silgan Holdings Inc. also operate in the market.

Additionally, owing to the rising technology integration, various emerging companies such as Kedalion Therapeutics, Inc., Re-Vana Therapeutics, Inc., Biocorp, and Ocumedic, Inc. are also present in the market and are developing advanced ophthalmic drug delivery devices.

The factors driving growth include increasing prevalence of ocular disorders, development of novel drug dispensers, integration of digital solutions in ophthalmic drug delivery devices, and regular funding cycles for emerging companies. The restraints for the global ophthalmic drug delivery devices market include high upfront cost of the advanced ophthalmic drug delivery devices and prolonged regulatory approval process. Furthermore, there are various opportunities in the market that hold considerable growth potential. Entry of regional companies in the global ophthalmic drug delivery devices market, partnerships between companies and ophthalmic clinics, and inclusion of nanotechnology in ophthalmic drugs formulation are the key opportunity areas in the global ophthalmic drug delivery devices market.

Key technology trends such as the sustained drug delivery, connected devices for medication adherence, small molecules for drug delivery, and liquid sprays are anticipated to influence the global ophthalmic drug delivery devices market.

The global ophthalmic drug delivery devices market is in early stages of technology integration. A limited number of patents have been filed in the global market between January 2016-July 2021. According to World Intellectual Property Organisation (WIPO), there were only 148 patents filed pertaining to the global market, with the highest being filed in 2017 (46).

During January 2018-June 2021, the global ophthalmic drug delivery devices market witnessed 54 key developments. Regulatory and legal activities were the most actively employed strategies, followed by mergers and acquisitions. The key companies that received regulatory approvals between January 2018-June 2021 included Ocular Therapeutix, Inc., AptarGroup, Inc., EyePoint Pharmaceuticals, Inc., Nemera, Johnson, and Johnson Medical Devices Companies, Bausch and Lomb Incorporated, Ocumedic, Inc, and Terumo Corporation. Similarly, several partnerships took place between January 2018-June 2021. The aim of strategic partnerships includes new product development and business expansion.

New product launches are one of the primary strategies adopted by new companies to enter the global ophthalmic drug delivery devices market. Companies have also been working on upgrades for their existing products. Between January 2018-June 2021, several new products were launched in the global ophthalmic drug delivery devices market. Companies such as Gerresheimer AG, Hoffman Neopac AG, Ocular Therapeutix, Inc., and Silgna Holdings, Inc. launched their products in the mentioned period. Furthermore, funding activities are critical for the entry and operation of start-ups in the global ophthalmic drug delivery devices market. Re-Vana Therapeutics, Credence MedSystems, Inc., and Kedalion Therapeutics, Inc. are the prominent companies in the global ophthalmic drug delivery devices market that have received funding for their product development and R&D efforts.

Two business models, namely, business-to-customer (B2C) and business-to-business (B2B), are operational in the global ophthalmic drug delivery devices market. The device manufacturers often employ both the business models for ensuring a prominent local and global presence. Moreover, owing to the emergence of add-on devices, the adoption of B2C business model is projected to increase in the market.

The global ophthalmic drug delivery devices market report highlights that the market was valued at $295.4 million in 2020 and is expected to reach $537.8 million by the end of 2030. The market is expected to grow at a CAGR of 6.17% during the forecast period from 2021 to 2030.

Global Ophthalmic Drug Delivery Devices Market Drivers

The factors driving growth include increasing prevalence of ocular disorders, development of novel drug dispensers, integration of digital solutions in ophthalmic drug delivery devices, and regular funding cycles for emerging companies. The rising prevalence of ocular disorders has also increased the global prevalence of blindness. For instance, according to a study published in Lancet, in December 2020, titled ‘Causes of Blindness and Vision Impairment In 2020 and Trends Over 30 Years, and Prevalence of Avoidable Blindness in Relation to VISION 2020: The Right to Sight: An Analysis for the Global Burden of Disease Study,’ cataract was the major cause of blindness. Furthermore, other ocular disorders such as glaucoma, uncorrected refractive error, age-related macular degeneration, and diabetic retinopathy are also the causes of blindness.

To overcome the shortcomings of conventional eye droppers, various companies operating in the market have developed either novel dispensing systems or advanced eyedroppers. For instance, companies such as AptarGroup, Inc. and Owen Mumford have developed squeeze dispensers for ophthalmic drug delivery. Furthermore, companies such as Nemera, Aero Pump GmbH, and Berry Healthcare have developed advanced eye droppers with a focus on preservative-free formulation and ease of usage.

Furthermore, owing to the rising digitization in the global healthcare system, advancements in drug delivery systems, rising focus on medication adherence, and high cost of drug non-adherence, the ophthalmic drug delivery devices have witnessed digital solutions integration. Companies such as Nemera have developed digital devices for ensuring medication adherence and compliance with the prescribed therapy by the patient. Furthermore, Aptar Group, Inc., in association with Kali Care, has developed connected solutions for ensuring optimum eye care.

Furthermore, emerging companies such as Kedalion Therapeutics, Inc., Re-Vana Therapeutics, and Ocumedic, Inc also operate in the global ophthalmic drug delivery devices market. These companies have a strong product pipeline of advanced drug delivery devices with a focus on minimal drug wastage. Moreover, the companies receive regular fundings that ensure constant product development and research and development (R&D) activities.

Global Ophthalmic Drug Delivery Devices Market Challenges

The restraints for the global ophthalmic drug delivery devices market include high upfront cost of the advanced ophthalmic drug delivery devices and prolonged regulatory approval process.

The high upfront cost of the advanced ophthalmic drug delivery devices plays a pivotal role in their limited adoption. For instance, the average price of an ocular insert is approximately $10 per unit, whereas the average price of a pre-filled syringe varies between $0.02-$0.60 per unit. Similarly, the price of a multidose eyedropper varies between $0.03-$0.12. The high price of the advanced ophthalmic drug delivery devices makes their purchase dependent on the reimbursable amount and eligibility criteria. Furthermore, the sales of such devices are considerably low in countries with only private insurance systems.

Furthermore, owing to the long duration of regulatory process and additional requirements, the cost of the process increases that further limits the new product launches. Furthermore, the product undergoes the regulatory process in each geography prior to its launch.

Global Ophthalmic Drug Delivery Devices Market Opportunities

Entry of regional companies in the global ophthalmic drug delivery devices market, partnerships between companies and ophthalmic clinics, and inclusion of nanotechnology in ophthalmic drugs formulation are the key opportunity areas in the global ophthalmic drug delivery devices market.

The global ophthalmic drug delivery devices market is dominated by global companies such as Nemera, Aptar Group, Inc., Becton, Dickinson and Company, and West Pharmaceutical Services, Inc. However, the market holds significant growth potential for regional companies as well. For instance, Chinese companies are one of the major global suppliers for pre-filled syringes and multidose eyedroppers.

Moreover, companies can partner with chain or standalone clinics as business expansion opportunities. Furthermore, partnerships with clinics also facilitate real-world evidence analysis for the companies. The key advantages of such a partnership for a company include the development of a customer base and market presence. Moreover, for patients and ophthalmologists, such a partnership would enable access to advanced drug delivery devices, increased compliance with therapy, and minimal wastage of the drugs.

Nanotechnology is one of the key technologies that can be used in manufacturing drug formulations. The key advantages of the technology include sustained drug delivery, target delivery, minimal wastage, and cost-efficacy. Furthermore, such formulations can pass through barriers such as cornea and can be used instead of invasive techniques such as implants.

Impact of COVID-19 on Global Ophthalmic Drug Delivery Devices Market

In the short term, i.e., 2-4 years from 2020, COVID-19 would have a medium impact on the global ophthalmic drug delivery devices market. The demand for add-on devices is anticipated to be high during this timeframe.

5-10 years from 2020, the resumption of elective surgeries and normalization of the supply chain would be the key factors for market recovery. Finally, in the long term, i.e., 8-12 years from 2020, the reinstatement of supply chain and entry of advanced ophthalmic drug delivery devices are expected.

Market Segmentation

Global Ophthalmic Drug Delivery Devices Market (by Product)

The global ophthalmic drug delivery devices market (by product) has been segmented into pre-filled syringes, multidose eyedroppers, contact lenses, add-on devices, mist sprayers, squeeze dispensers, and others.

Global Ophthalmic Drug Delivery Devices Market (by Formulation)

The global ophthalmic drug delivery devices market (by formulation) has been segmented into eye drops, liquid sprays, ointments, gels, and others.

Global Ophthalmic Drug Delivery Devices Market (by Sales Channel)

The global ophthalmic drug delivery devices market has been segmented into direct sales and indirect sales.

Global Ophthalmic Drug Delivery Devices Market (by End User)

The global ophthalmic drug delivery devices market (by end user) has been segmented into hospitals, clinics, homecare settings, and others

Global Ophthalmic Drug Delivery Devices Market (by Region)

The different regions covered under the global ophthalmic drug delivery devices market report include North America, Europe, Asia-Pacific, Latin America, and the Middle East, and Africa.

North America dominated the global ophthalmic drug delivery devices market in 2018 and is anticipated to uphold its dominance throughout the forecast period. The growth in the market is majorly driven by the increasing research and development activities and adoption of advanced ophthalmic drug delivery devices. Also, the ongoing trend for digital transformation through the development of platforms and mobile applications is putting a significant impact on the market growth.

Key Market Players and Competition Synopsis

Aero Pump GmbH, AptarGroup, Inc., Bausch Health Companies Inc., Becton, Dickinson and Company, EyePoint Pharmaceuticals, Inc., Gaplast GmbH, Gerresheimer AG, Jotteq Inc., Nemera, Nipro Corporation, Ocular Therapeutix, Inc., Owen Mumford, Silgan Holdings Inc., Terumo Corporation, West Pharmaceutical Services, Inc., Kedalion Therapeutics, Inc., Re-Vana Therapeutics, Mati Therapeutics, Inc., Biocorp, and Ocumedic, Inc.

The global ophthalmic drug delivery devices market has witnessed several strategic and technological developments in the past few years undertaken by the different market players to attain their respective market shares in this emerging domain. Some of the strategies covered in this segment are regulatory and legal activities, partnerships and alliances, new offerings, mergers and acquisitions, expansion activities, and funding activities.

Global Advanced Dermatology Drug Delivery Devices Market: Focus on Product Type, Volume Sold, Analysis and Forecast 2021-2030

The post Global Ophthalmic Drug Delivery Devices Market: Focus on Product, Formulation, Sales Channel, End User, and 21 Countries – Analysis and Forecast, 2021-2030 first appeared on CRI Report.

Market Segmentation

• Application (Sleep Disorders, Neurophysiology, Brain-Computer Interface, Cognitive Neuroscience, Neuromarketing, and Others)
• End User (Research and Academic Institutes, and Labs, Hospitals, Home Care Settings, and Others)

Regional Segmentation

• North America – U.S., Canada
• Europe – Germany, France, U.K., Italy, Spain, and Rest-of-Europe
• Asia-Pacific – China, Japan, South Korea, India, Australia, and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, and Rest-of-the-Latin America
• Middle East and Africa

Growth Drivers

• Use of Wireless Brain Sensors for the Diagnosis of Sleep Disorders
• Growing Incidence of Neurological Disorders
• Increasing Applications of Advanced Sensors in Neurological Devices
• Growing Geriatric Population

Market Challenges

• Stringent Regulatory Policies
• Risk of Product Recalls and High Cost of the Devices

Market Opportunities

• Technological Advancements in Wireless Brain Sensors Market
• Regional Expansion and Increasing Adoption of Wireless Brain Sensors in Emerging Economies

Key Companies Profiled

Compumedics Limited, Wearable Sensing, Medtronic Plc, Natus Medical Incorporated, Brain Scientific, Inc, and Nihon Kohden Corporation, EMOTIV, Advanced Brain Monitoring, Inc, Brain Products GmbH, NeuroSky, Neuroelectrics, Cadwell Industries, Inc, Jordan Neuroscience, Inc, BrainScope Company, Inc, and Muse, among others

Key Questions Answered in this Report:

• How has COVID-19 impacted the global wireless brain sensors market?
• What are the key regulations for the development, commercialization, and adoption of wireless brain sensors?
• Which are the leading players that currently hold significant dominance in the global wireless brain sensors market?
• What are the key strategies incorporated by the players of the global wireless brain sensors market to sustain the competition and retain their supremacy?
• What is the patent landscape of the wireless brain sensors market?
• What are the key technological developments on which the current industry leaders are spending their major share of research and development (R&D) investment?
• What is the current market potential of wireless brain sensors, and what factors decide the growth potential of wireless brain sensors for the forecast period?
• What is the current revenue contribution of different products, and how would it evolve in the forecast period?
• Which application contributes to the highest CAGR (%) in the global wireless brain sensors market?
• How does the end-user perception impact the growth of the global wireless brain sensors market?
• Which countries contribute to a major share of the current demand, and which countries hold significant scope for expansion for business activities by players of the global wireless brain sensors market?
• What are the drivers, restraints, and opportunities in the global wireless brain sensors market?

Key USPs of the Report

Following are some of the key contents of the report:

• Funding Scenario
This section encompasses a description of the current funding landscape in the global wireless brain sensors space for key players.

• Regulatory Approved Products
This section includes information on regulatory approved wireless brain sensor products in the market.

• Business Model Analysis
This section comprises information on the key business models deployed in the market by leading players.

• Impact of COVID-19
This section of the report encompasses the following:
o Short-, Mid-, and Long-Term Impact on Wireless Brain Sensors Market
o Regional Impact of COVID-19 Industry
o Entry Barriers and Opportunities for the Companies in Global Wireless Brain Sensors Market

In addition, the report provides:

• A detailed analysis and growth forecast (2021-2030) for different market segments
• Recent developments and trends in the global market landscape
• Factors promoting and inhibiting the market growth
• Case studies to assess the delivery models and strategies adopted by some of the highly funded players in the market

Expert Quote

“In order to gain a competitive share in the wireless brain sensor market, various small-scale and mid-scale companies are collaborating with government organizations and private investors to have significant funding for the development and commercialization of technically advanced wireless brain sensor products across different regions of the world. Ceribell, Inc, BrainScope, and Neural Analytics are some companies which received more than $10 million funding from finance and private investors for their products”.

Scope of the Global Wireless Brain Sensor Market

The purpose of the study is to enable the reader to gain a holistic view of the global wireless brain sensors market by each of the segments mentioned above in the table.

The report constitutes an in-depth analysis of the global wireless brain sensors market, including a thorough analysis of the applications. The study also provides market and business-related information on various applications and end users.

The post Global Wireless Brain Sensors Market: Analysis and Forecast, 2021-30 first appeared on CRI Report.